December 15th, 2015

Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug after prior rejection

[Reuters] – By a lopsided vote of 13 to 1, an independent committee of medical experts on Thursday voted to recommend approval of a new type of diabetes drug from Bristol-Myers Squibb that . . . → Read More: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug after prior rejection Similar posts: Merck & Co. Inc. (NYSE:MRK) – FDA panel says Merck’s allergy drug effective Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may work, but risky -FDA staff Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe

Bristol-Myers Squibb Company (NYSE:BMY) [Reuters] – By a lopsided vote of 13 to 1, an independent committee of medical experts on Thursday voted to recommend approval of a new type of diabetes drug from Bristol-Myers Squibb that U.S. regulators rejected two years ago due to safety concerns. The advisory panel to the U.S. Food and Drug Administration on Thursday said the benefits of the medicine, called dapaglifozin, appear to outweigh its risks. Bristol-Myers is developing the drug, which is already approved … [visit site to read more]

Similar posts:
  1. Merck & Co. Inc. (NYSE:MRK) – FDA panel says Merck’s allergy drug effective
  2. Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may work, but risky -FDA staff
  3. Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.